Halozyme Therapeutics Inc
1 member of Congress bought
Stocks scoring 0–25 beat the S&P 500 39.9% of the time over the next three months, since 2015. How we measured this →
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption…
| Trade date | Member | Chamber | Action | Amount |
|---|---|---|---|---|
| 2026-09-29 | Gilbert Ray Cisneros, Jr. · D-CA | House | Sold | $1,001 - $15,000 |
| 2026-03-09 | Gilbert Ray Cisneros, Jr. · D-CA | House | Bought | $1,001 - $15,000 |
| 2025-03-24 | Gilbert Ray Cisneros, Jr. · D-CA | House | Sold | $1,001 - $15,000 |
| 2024-09-09 | Josh Gottheimer · D-NJ | House | Sold | $1,001 - $15,000 |
| 2023-07-12 | Daniel S. Goldman · D-NY | House | Sold | $15,001 - $50,000 |
| 2022-12-06 | Josh Gottheimer · D-NJ | House | Sold | $1,001 - $15,000 |
| 2022-08-05 | Josh Gottheimer · D-NJ | House | Sold | $1,001 - $15,000 |
| 2021-08-20 | Josh Gottheimer · D-NJ | House | Bought | $1,001 - $15,000 |
| 2020-10-22 | Gilbert Ray Cisneros, Jr. · D-CA | House | Bought | $1,001 - $15,000 |
| 2020-10-19 | Josh Gottheimer · D-NJ | House | Bought | $1,001 - $15,000 |
Show the other 1
| Trade date | Member | Chamber | Action | Amount |
|---|---|---|---|---|
| 2017-11-06 | Mark R. Warner · D-VA | Senate | Sold | $500,001 - $1,000,000 |
Markers sit on the transaction date the member disclosed, snapped to the nearest close on the chart. They are not the date the public found out — that came later, and the gap is its own page. Every marker is listed by name in the table above.